ClinicaliQ Trial Snapshot
- A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years — Recruiting • Phase II • Neurology • NCT06735248.
- Treatment being tested: mRNA-1195, a novel mRNA-based therapeutic, is being investigated for its safety profile and tolerability in multiple sclerosis patients, with evaluation of relapse prevention as a secondary outcome.
- Patient eligibility overview: The trial enrolls adults aged 18–55 years with multiple sclerosis; specific disease type and activity status criteria would determine which MS patients qualify for participation.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.
Eligibility Snapshot
- : * Medically stable as determined by Investigator's medical evaluation, which will include assessment of medical history, physical examination, laboratory testing, and review of any previously conducted cardiac monitoring. * Participants who are Epstein-Barr virus (EBV)-seropositive at screening. * Participants diagnosed with relapsing multiple sclerosis, including those with a single clinical attack (that is, clinically isolated syndrome [CIS]), as well as participants diagnosed with radiologically isolated syndrome, within 24 months of Screening Visit (that is, early in their multiple sclerosis course) and in the opinion of the Investigator have been neurologically stable for at least 30 days prior to Visit 1/Day 1. * A participant who could become pregnant is eligible to participate if they are not pregnant or breast/chest feeding and using a highly effective contraceptive method.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.